Friday October 20th 2017

NICE recommends once-daily oral medicine Aubagio® for the treatment of active relapsing remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) today issued its final guidance recommending that Aubagio® (teriflunomide 14 mg) should be reimbursed within the National Health Service (NHS) for the treatment of adults with active relapsing remitting multiple sclerosis (RRMS).

See the original article here: 

NICE recommends once-daily oral medicine Aubagio® for the treatment of active relapsing remitting multiple sclerosis

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]